Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Empagliflozin: Phase III data

A double-blind Phase III trial in 666 Type II diabetics showed that once-daily 10 and 25 mg empagliflozin as an add-on to metformin plus sulfonylurea

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE